Osteolysis and cancer

Journal of Clinical Investigation

Volumn 107, Issue 10, 2001, Pages 1219-1220

  Goltzman, David ^a,b,c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR; ICOSANOID; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ANIMAL MODEL; BONE MATRIX; BONE METASTASIS; CANCER THERAPY; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; NOTE; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL;

EID: 0035009069     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI13073     Document Type: Note

References (20)

1. Mechanisms of the development of osteoblastic metastases
2. Molecular basis of the spectrum of skeletal complications of neoplasia
3. Direct resorption of bone by human breast cancer cells in vitro
4. The molecular basis of osteoclast differentiation and activation
5. Osteoprotegerin ligand: A regulator of immune responses and bone physiology
6. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation
7. Molecular mechanisms of osteolytic bone metastases
8. Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo
9. Molecular mechanisms of tumor-bone interactions in osteolytic metastases
10. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy
11. Cellular and molecular mechanisms of action of bisphosphonates
12. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro
13. Bisphosphonates induce apoptosis in human breast cancer cell lines
14. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: Uncoupling of bone cell activity
15. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis
16. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone
17. Bisphosphonates in the treatment of malignant bone disease
18. Breast cancer cells interact with osteoblasts to support osteoclast formation
19. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro
20. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF-TRANCE that induces osteoclast formation